Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 17, 2017 - Issue 2
Submit an article Journal homepage
922
Views
16
CrossRef citations to date
0
Altmetric
Clinical Trial Report

Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype

Anirban BasuPharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USAView further author information
,
Anand DalalUS Value, Evidence and Outcomes, US Medical Affairs, GlaxoSmithKline, Durham, NC, USAView further author information
,
Giorgio Walter CanonicaPersonalized Medicine Asthma & Allergy Clinic Humanitas University, IRCCS-Humanitas Research Hospital, Rozzano-Milano, ItalyView further author information
,
Mark ForshagUS Medical Affairs, Respiratory Therapeutic Area, GlaxoSmithKline, Durham, NC, USAView further author information
,
Steven W. YanceyR&D, Respiratory Therapeutic Area Unit, GlaxoSmithKline, Durham, NC, USAView further author information
,
Saurabh NagarHealth Economics, RTI-Health Solutions, Research Triangle Park, NC, USAView further author information
&
Christopher F. BellUS Value, Evidence and Outcomes, US Medical Affairs, GlaxoSmithKline, Durham, NC, USACorrespondence[email protected]
View further author information
 show all
Pages 121-131 | Received 01 Nov 2016, Accepted 20 Feb 2017, Published online: 17 Mar 2017

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Javier Domínguez-Ortega, Daniel Laorden, Francisca Vílchez-Sánchez, David Bañas-Conejero & Santiago Quirce. (2023) Cost-effectiveness and resource use analysis of patients with asthma before and after treatment with mepolizumab in a real-life setting. Journal of Asthma 0:0, pages 1-9.
Read now
Sara Alves, João Cavaleiro Rufo & José Crispim. (2023) Economic evaluation of biological treatments in patients with severe asthma: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 23:7, pages 733-747.
Read now
Maria De Filippo, Martina Votto, Amelia Licari, Fabio Pagella, Marco Benazzo, Giorgio Ciprandi & Gian Luigi Marseglia. (2021) Novel therapeutic approaches targeting endotypes of severe airway disease. Expert Review of Respiratory Medicine 15:10, pages 1303-1316.
Read now
Carlo Cavaliere, Franco Frati, Erminia Ridolo, Antonio Greco, Marco de Vincentiis, Simonetta Masieri, Eleni Makri & Cristoforo Incorvaia. (2019) The spectrum of therapeutic activity of mepolizumab. Expert Review of Clinical Immunology 15:9, pages 959-967.
Read now

Articles from other publishers (12)

Hiroyuki Nagase, Jun Tamaoki, Takeo Suzuki, Yasuko Nezu, Shoko Akiyama, Ashley L. Cole, Shibing Yang, George Mu, Masayuki Katsumata, Masaki Komatsubara & Rafael Alfonso-Cristancho. (2022) Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan. Pulmonary Pharmacology & Therapeutics 75, pages 102130.
Crossref
Hugo A Farne, Amanda Wilson, Stephen Milan, Emma Banchoff, Freda Yang & Colin VE Powell. (2022) Anti-IL-5 therapies for asthma. Cochrane Database of Systematic Reviews 2022:7.
Crossref
Maruša Kopač Šokić, Matija Rijavec, Peter Korošec, Urška Bidovec-Stojkovič, Izidor Kern, Romana Vantur & Sabina Škrgat. (2022) Heterogeneous Response of Airway Eosinophilia to Anti-IL-5 Biologics in Severe Asthma Patients. Journal of Personalized Medicine 12:1, pages 70.
Crossref
Michele Ghezzi, Elena Pozzi, Luisa Abbattista, Luisa Lonoce, Gian Vincenzo Zuccotti & Enza D’Auria. (2021) Barrier Impairment and Type 2 Inflammation in Allergic Diseases: The Pediatric Perspective. Children 8:12, pages 1165.
Crossref
Giovanna Elisiana Carpagnano, Emanuela Resta, Massimiliano Povero, Corrado Pelaia, Mariella D’Amato, Nunzio Crimi, Nicola Scichilone, Giulia Scioscia, Onofrio Resta, Cecilia Calabrese, Girolamo Pelaia & Maria Pia Foschino Barbaro. (2021) Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma. Scientific Reports 11:1.
Crossref
Diego Bagnasco, Massimiliano Povero, Lorenzo Pradelli, Luisa Brussino, Giovanni Rolla, Marco Caminati, Francesco Menzella, Enrico Heffler, Giorgio Walter Canonica, Pierluigi Paggiaro, Gianenrico Senna, Manlio Milanese, Carlo Lombardi, Caterina Bucca, Andrea Manfredi, Rikki Frank Canevari, Giovanni Passalacqua, Gabriella Guarnieri, Vincenzo Patella, Foschino Barbaro Maria Pia, Elisiana Carpagnano, Anna del Colle, Giulia Scioscia, Pelaia Gerolamo, Pierluigi Paggiaro, Manuela Latorre, Francesca Puggioni, Francesca Racca, Elisabetta Favero, Sandra Iannacone, Eleonora Savi, Marcello Montagni, Gianna Camiciottoli, Chiara Allegrini, Giuseppe Spadaro, Caterina Detoraki, Carla Galeone, Patrizia Ruggiero, Monna Rita Yacoub, Alvise Berti, Gisella Colombo, Nicola Scichilone, Carmen Durante, Maria Teresa Costantino, Chiara Roncallo, Mariachiara Braschi, Francesco Blasi, Alice D'Adda, Erminia Ridolo, Massimo Triggiani, Roberta Parente, D'Amato Maria, Maria Vittoria Verrillo, Zappa Maria Cristina, Marianna Lilli, Nunzio Crimi, Marco Bonavia, Angelo Guido Corsico, Amelia Grosso, Stefano Del Giacco, Margherita Deidda, Luisa Ricciardi, Stefania Isola, Francesca Cicero, Giuliana Amato, Federica Vita, Antonio Spanevello, Patrizia Pignatti, Francesca Cherubino, Dina Visca, Eleonora Aletti, Fabio Luigi Massimo Ricciardolo, Vitina Maria Anna Carriero, Francesca Bertolini, Pierachille Santus, Roberta Barlassina, Andrea Airoldi, Giuseppe Guida, Nucera Eleonora, Arianna Aruanno, Angela Rizzi, Cristiano Caruso, Stefania Colantuono, Alessandra Arcolaci, Andrea Vianello, Fulvia Chieco Bianchi, Maria Rita Marchi, Stefano Centanni, Simone Luraschi, Silvia Ruggeri, Rocco Rinaldo, Elena Parazzini, Cecilia Calabrese, Martina Flora, Lorenzo Cosmi, Linda Di Pietro, Enrico Maggi, Laura Pini, Luigi Macchia, Danilo Di Bona, Luca Richeldi, Carola Condoluci, Leonello Fuso, Matteo Bonini, Alessandro Farsi, Giulia Carli, Paolo Montuschi, Giuseppe Santini, Maria Elisabetta Conte, Elisa Turchet, Carlo Barbetta, Francesco Mazza, Simona D'Alo, Stefano Pucci, Maria Filomena Caiaffa, Elena Minenna, Luciana D'Elia, Carlo Pasculli, Vittorio Viviano, Paolo Tarsia, Joyce Rolo, Mariacarmela Di Proietto, Salvatore Lo Cicero & Mariacarmela Di Proietto. (2021) Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organization Journal 14:2, pages 100509.
Crossref
Renee R. Koski & Kirsten M. Grzegorczyk. (2019) Comparison of Monoclonal Antibodies for Treatment of Uncontrolled Eosinophilic Asthma. Journal of Pharmacy Practice 33:4, pages 513-522.
Crossref
Seiko Soeda, Yuta Kono, Ryuta Tsuzuki, Satoshi Yamawaki, Otohiro Katsube, Masako To & Yasuo To. (2019) Allergic bronchopulmonary aspergillosis successfully treated with benralizumab. The Journal of Allergy and Clinical Immunology: In Practice 7:5, pages 1633-1635.
Crossref
Nora Drick, Benjamin Seeliger, Tobias Welte, Jan Fuge & Hendrik Suhling. (2018) Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response. BMC Pulmonary Medicine 18:1.
Crossref
Philippe Lavigne & Stella E. Lee. (2018) Immunomodulators in chronic rhinosinusitis. World Journal of Otorhinolaryngology - Head and Neck Surgery 4:3, pages 186-192.
Crossref
Gail M. Gauvreau, Beth E. Davis & John Paul Oliveria. 2018. Oligonucleotide‐Based Drugs and Therapeutics. Oligonucleotide‐Based Drugs and Therapeutics 355 388 .
Hugo A Farne, Amanda Wilson, Colin Powell, Lynne Bax & Stephen J Milan. (2017) Anti-IL5 therapies for asthma. Cochrane Database of Systematic Reviews.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.